Status:
COMPLETED
A Study to See How Safe and Tolerable Different Doses of REGN13335 Are When Administered Intravenously (IV) or Subcutaneously (SC) to Healthy Adult Participants
Lead Sponsor:
Regeneron Pharmaceuticals
Conditions:
Healthy Volunteers
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
This study is researching an experimental drug called REGN13335. This is the first time that REGN13335 will be given to people. This study will enroll healthy adults. The aim of the study is to see h...
Eligibility Criteria
Inclusion
- Key
- Has a body mass index between 18 and 32 kg/m\^2, inclusive, at the screening visit
- Is judged by the investigator to be in good health based on medical history, physical examination, vital sign measurements, laboratory safety tests, and electrocardiograms (ECGs) performed prior to administration of study drug (ie, screening and baseline visit)
- Key
Exclusion
- 1\. History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric or neurological disease, as assessed by the investigator
- NOTE: Other Protocol Defined Inclusion / Exclusion Criteria Apply.
Key Trial Info
Start Date :
December 6 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 11 2025
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT06137482
Start Date
December 6 2023
End Date
February 11 2025
Last Update
March 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New Zealand Clinical Research
Christchurch, Canterbury, New Zealand, 8011